BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20009002)

  • 21. Pediatric Extranodal Lymphoma.
    Chung EM; Pavio M
    Radiol Clin North Am; 2016 Jul; 54(4):727-46. PubMed ID: 27265605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testicular fluorine-18 fludeoxyglucose uptake on positron emission tomography CT in patients with lymphoma: clinical significance and management impact.
    Sidhu P; Lin P; Son H; Rosenfeld D; Lin M
    Br J Radiol; 2014 Dec; 87(1044):20140472. PubMed ID: 25333503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Jiang Y; Wang L; Zhou W; Gu J; Tian Y; Dong Y; Fu L; Wu HB
    Cancer Imaging; 2020 Jan; 20(1):4. PubMed ID: 31924270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectrum of FDG PET/CT findings in Burkitt lymphoma.
    Zeng W; Lechowicz MJ; Winton E; Cho SM; Galt JR; Halkar R
    Clin Nucl Med; 2009 Jun; 34(6):355-8. PubMed ID: 19487844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. F-18 FDG PET/CT in primary tonsillar lymphoma.
    Zhang MJ; Jiang JJ; Jiang MS; He W
    Clin Nucl Med; 2010 Sep; 35(9):710-2. PubMed ID: 20706049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET/computed tomography and lymphoma.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nodal staging of lymphoma with whole-body PET: comparison of.
    Sutinen E; Jyrkkiö S; Varpula M; Lindholm P; Grönroos T; Lehikoinen P; Teräs M; Minn H
    J Nucl Med; 2000 Dec; 41(12):1980-8. PubMed ID: 11138682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL; Chen S; Yeung DW; Cheng TK
    J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
    Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
    Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
    Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
    Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
    Basu S; Mahne A; Iruvuri S; Alavi A
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
    Khong PL; Pang CB; Liang R; Kwong YL; Au WY
    Ann Hematol; 2008 Aug; 87(8):613-21. PubMed ID: 18509641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma.
    Perry C; Herishanu Y; Metzer U; Bairey O; Ruchlemer R; Trejo L; Naparstek E; Sapir EE; Polliack A
    Eur J Haematol; 2007 Sep; 79(3):205-9. PubMed ID: 17662066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas.
    Chan WK; Au WY; Wong CY; Liang R; Leung AY; Kwong YL; Khong PL
    Clin Nucl Med; 2010 Aug; 35(8):571-5. PubMed ID: 20631501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.